Stock comparison
Bio-Rad Laboratories
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIO
Bio-Rad Laboratories
Market cap
$7.78B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIO | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 69B | MTD |
| Benjamin Graham | 48D | 65B | MTD |
| Philip Fisher | 30F | 63C | MTD |
| Peter Lynch | 10F | 66B | MTD |
| Joel Greenblatt | 42D | 68B | MTD |
| Charlie Munger | 34F | 74B | MTD |
| Terry Smith | 26F | 70B | MTD |
Side-by-side metrics
| Metric | BIO | MTD |
|---|---|---|
| Market cap | $7.78B | $22.29B |
| P/E (TTM) | 39.5x | 25.3x |
| EV/EBIT | 28.0x | 21.6x |
| ROIC (TTM) | 1.95% | 36.09% |
| Gross margin | 51.87% | 57.79% |
| Net margin | 6.52% | 21.4% |
| Revenue CAGR 5y | -3.04% | 2.01% |
| EPS CAGR 5y | -33.51% | 6.12% |
| Debt / Equity | 0.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIO leads on
No clear edges - the other side wins or ties on every measured metric.
MTD leads on
- Revenue CAGR 5y2.01%vs -3.04%+166%
- EPS CAGR 5y6.12%vs -33.51%+118%
- Debt / Equity-vs 0.2x+100%
- ROIC (TTM)36.09%vs 1.95%+95%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.